{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T01:32:26Z","timestamp":1774747946549,"version":"3.50.1"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Small-cell lung cancer (SCLC) is a highly malignant neuroendocrine tumour, and concurrent chemoradiotherapy is the current recommended treatment for limited-stage SCLC. However, the overall survival (OS) of patients with SCLC remains poor. Therefore, improving the survival of patients with SCLC and benefitting more patients are urgent clinical requirements. Immunotherapy has achieved good efficacy in extensive-stage SCLC and non-SCLC. However, the use of neoadjuvant immunotherapy in limited-stage SCLC is unknown but promising. To this end, we plan to conduct a study on adebrelimab in combination with chemotherapy for the neoadjuvant treatment of limited-stage SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This will be a single-arm, prospective study. The primary endpoint of this study will be a pathological complete remission rate. The secondary endpoints will be a major pathological response, objective response rate, event-free survival, OS, R0 resection rate, safety and potential predictive biomarker parameters related to efficacy in peripheral blood samples, including minimal residual disease, circulating tumour cells and cluster of differentiation (CD) 4\/CD8. This study will enrol 28 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the Biomedical Ethics Review Committee of West China Hospital, Sichuan University, on 1 August 2023 (grant number 2023[987]). The version of this study protocol is V7.0. The patients have been enrolled since September 2023. This study will conclude in January 2026, and the results will be presented to peer-reviewed medical journals and international scientific conferences in 2027. This study will provide important data on whether neoadjuvant treatment with adebrelimab combined with chemotherapy is clinically beneficial in patients with limited-stage SCLC.<\/jats:p>\n                    <jats:p>\n                      (Prospective study of neoadjuvant adebrelimab combined with chemotherapy in limited-stage SCLC; Chinese Clinical Trial Registry (ChiCTR),\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.chictr.org.cn\/\">www.chictr.org.cn\/<\/jats:ext-link>\n                      ; Number, ChiCTR2300074591.)\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2300074591<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087302","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:05:59Z","timestamp":1736640359000},"page":"e087302","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant adebrelimab combined with chemotherapy (cisplatin\/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS)"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-4525","authenticated-orcid":false,"given":"Yanyang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Tian","sequence":"additional","affiliation":[{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guizhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, No 363 Hospital, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxia","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center, Army Medical University Daping Hospital, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daxing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-2053","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"2025121408460847000_15.1.e087302.1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J Clinicians"},{"key":"2025121408460847000_15.1.e087302.2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0736-3"},{"key":"2025121408460847000_15.1.e087302.3","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.00000000 00001474"},{"key":"2025121408460847000_15.1.e087302.4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0079"},{"key":"2025121408460847000_15.1.e087302.5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0298"},{"key":"2025121408460847000_15.1.e087302.6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jtho.2020.10.020","article-title":"American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020","volume":"16","author":"Chun","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025121408460847000_15.1.e087302.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24853"},{"key":"2025121408460847000_15.1.e087302.8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12957-020-1807-1","article-title":"Prognosis of limited-stage small cell lung cancer with comprehensive treatment including radical resection","volume":"18","author":"Zhong","year":"2020","journal-title":"World J Surg Oncol"},{"key":"2025121408460847000_15.1.e087302.9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtcvs.2020.10.148","article-title":"Predictors of survival following surgical resection of limited-stage small cell lung cancer","volume":"161","author":"Zhou","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025121408460847000_15.1.e087302.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2025121408460847000_15.1.e087302.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"2025121408460847000_15.1.e087302.12","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"The Lancet"},{"key":"2025121408460847000_15.1.e087302.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"2025121408460847000_15.1.e087302.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"2025121408460847000_15.1.e087302.15","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1097\/JS9.0000000000000501","article-title":"A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab in combination with chemotherapy in resectable small cell lung cancer (Cohort Study)","volume":"109","author":"Duan","year":"2023","journal-title":"Int J Surg"},{"key":"2025121408460847000_15.1.e087302.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1111325","article-title":"Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"2025121408460847000_15.1.e087302.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:46:12Z","timestamp":1765730772000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-087302"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087302","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}